Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Ag Postfinance sold 236,155 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $0.34, for a total value of $80,292.70. Following the sale, the insider now owns 5,311,451 shares of the company’s stock, valued at $1,805,893.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of Cytori Therapeutics Inc (NASDAQ CYTX) traded down $0.01 on Monday, hitting $0.31. The company had a trading volume of 556,715 shares, compared to its average volume of 2,460,000. Cytori Therapeutics Inc has a 52-week low of $0.22 and a 52-week high of $2.13. The stock has a market capitalization of $10.89, a PE ratio of -0.34 and a beta of 3.56.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The firm had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.04 million. During the same period in the previous year, the business earned ($0.26) earnings per share. equities analysts predict that Cytori Therapeutics Inc will post -0.62 EPS for the current fiscal year.

Several brokerages recently commented on CYTX. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 22nd. Zacks Investment Research upgraded Cytori Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

Several institutional investors and hedge funds have recently modified their holdings of CYTX. Perkins Capital Management Inc. grew its holdings in Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares in the last quarter. Sabby Management LLC grew its holdings in Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Hedge funds and other institutional investors own 10.82% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/02/12/cytori-therapeutics-inc-cytx-major-shareholder-sells-80292-70-in-stock.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.